Slower 3Q growth at Novo Nordisk as Victoza comes under pressure
This article was originally published in Scrip
Executive Summary
Novo Nordisk reported slower-than-expected growth of its blockbuster Victoza in the third quarter, contributing to the world's biggest insulin maker missing analysts' estimates for third quarter income. The company also noted in its 3Q announcement that from 31 October 2013, it is making all its trial data public.